How Phages Overcome the Challenges of Drug Resistant Bacteria in Clinical Infections

References

• Rex JH, Talbot GH, Goldberger MJ, et al. Progress in the fight against multidrug-resistant bacteria 2005–2016: modern noninferiority trial designs enable antibiotic development in advance of epidemic bacterial resistance. Clin Infect Dis. 2017;65:141–146. doi:10.1093/cid/cix24629017263
   PubMed Web of Science ®Google Scholar
• Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18:318–327. doi:10.1016/S1473-3099(17)30753-329276051
   PubMed Web of Science ®Google Scholar
• Bahramian A, Shariati A, Azimi T, et al. First report of New Delhi metallo-β-lactamase-6 (NDM-6) among Klebsiella pneumoniae ST147 strains isolated from dialysis patients in Iran. Infect Genet Evol. 2019b;69:142–145. doi:10.1016/j.meegid.2019.01.03030684646
   PubMed Web of Science ®Google Scholar
• Freire-Moran L, Aronsson B, Manz C, et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria—time to react is now. Drug Resist Updat. 2011;14:118–124. doi:10.1016/j.drup.2011.02.00321435939
   PubMed Web of Science ®Google Scholar
• Jain S. Emergence of colistin resistance among gram negative bacteria in urinary tract infections from super specialty hospital of North India. Int J Infect Dis. 2018;73:133. doi:10.1016/j.ijid.2018.04.3716
   Web of Science ®Google Scholar
• Mohebi S, Hossieni Nave H, Norouzi A, Kandehkar Gharaman M, Taati Moghadam M. Detection of extended spectrum beta lactamases on class I integron in escherichia coli isolated from clinical samples. J Mazandaran Univ Med Sci. 2016;26:66–76.
   Google Scholar
• Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem. 2014;6:S14459. doi:10.4137/PMC.S14459
   Google Scholar
• Hadizadeh M, Norouzi A, Taghadosi R, et al. Prevalence of qnr, intI, and intII genes in extendedspectrum beta-lactamase (ESBL)-producing Escherichia coli isolated from clinical samples in Iran. Trop J Pharm Res. 2017;16:141–147.
   Web of Science ®Google Scholar
• Yang Y-S, Wei W, Hu X-X, et al. Evolution and antibacterial evaluation of 8-hydroxy-cycloberberine derivatives as a novel family of antibacterial agents against MRSA. Molecules. 2019;24:984. doi:10.3390/molecules24050984
   Web of Science ®Google Scholar
• Boluki E, Kazemian H, Peeridogaheh H, et al. Antimicrobial activity of photodynamic therapy in combination with colistin against a pan-drug resistant Acinetobacter baumannii isolated from burn patient. Photodiagnosis Photodyn Ther. 2017;18:1–5. doi:10.1016/j.pdpdt.2017.01.00328088439
   PubMed Web of Science ®Google Scholar
• Khan SN, Khan AU. Breaking the spell: combating multidrug resistant ‘superbugs’. Front Microbiol. 2016;7:174. doi:10.3389/fmicb.2016.0017426925046
   PubMed Web of Science ®Google Scholar
• Sharahi JY, Azimi T, Shariati A, Safari H, Tehrani MK, Hashemi A. Advanced strategies for combating bacterial biofilms. J Cell Physiol. 2019;234:14689–14708. doi:10.1002/jcp.v234.9
   Web of Science ®Google Scholar
• Wright GD, Sutherland AD. New strategies for combating multidrug-resistant bacteria. Trends Mol Med. 2007;13:260–267. doi:10.1016/j.molmed.2007.04.00417493872
   PubMed Web of Science ®Google Scholar
• Burrowes B, Harper DR, Anderson J, Mcconville M, Enright MC. Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens. Expert Rev Anti Infect Ther. 2011;9:775–785. doi:10.1586/eri.11.9021905786
   PubMed Web of Science ®Google Scholar
• Kamal F, Dennis JJ. Burkholderia cepacia complex Phage-Antibiotic Synergy (PAS): antibiotics stimulate lytic phage activity. Appl Environ Microbiol. 2014;02850–14.
   Web of Science ®Google Scholar
• Knezevic P, Curcin S, Aleksic V, Petrusic M, Vlaski L. Phage-antibiotic synergism: a possible approach to combatting Pseudomonas aeruginosa. Res Microbiol. 2013;164:55–60. doi:10.1016/j.resmic.2012.08.00823000091
   PubMed Web of Science ®Google Scholar
• Mapes AC, Trautner BW, Liao KS, Ramig RF. Development of expanded host range phage active on biofilms of multi-drug resistant Pseudomonas aeruginosa. Bacteriophage. 2016;6:e1096995. doi:10.1080/21597081.2015.109699527144083
   PubMedGoogle Scholar
• Yin S, Huang G, Zhang Y, et al. Phage Abp1 rescues human cells and mice from infection by pan-drug resistant Acinetobacter baumannii. Cell Physiol Biochem. 2017;44:2337–2345. doi:10.1159/00048611729258062
   PubMedGoogle Scholar
• Hankin EH. L’action bactericide des eaux de la Jumna et du Gange sur le vibrion du cholera. Ann Inst Pasteur. 1896;10:11.
   Google Scholar
• Twort FW. Further investigations on the nature of ultra-microscopic viruses and their cultivation. Epidemiol Infect. 1936;36:204–235.
   Google Scholar
• D’Herelle M. Sur un microbe invisible antagoniste des bacilles dysentériques. Acta Kravsi; 1961.
   Google Scholar
• Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage. 2011;1:66–85. doi:10.4161/bact.1.2.1584522334863
   PubMedGoogle Scholar
• Gelman D, Eisenkraft A, Chanishvili N, Nachman D, Glazer SC, Hazan R. The history and promising future of phage therapy in the military service. J Trauma Acute Care Surg. 2018;85:S18–S26. doi:10.1097/TA.000000000000180929370056
   PubMed Web of Science ®Google Scholar
• Cisek AA, Dąbrowska I, Gregorczyk KP, Wyżewski Z. Phage therapy in bacterial infections treatment: one hundred years after the discovery of bacteriophages. Curr Microbiol. 2017;74:277–283. doi:10.1007/s00284-016-1166-x27896482
   PubMed Web of Science ®Google Scholar
• Salmond GP, Fineran PC. A century of the phage: past, present and future. Nat Rev Microbiol. 2015;13:777. doi:10.1038/nrmicro356426548913
   PubMed Web of Science ®Google Scholar
• Kutter E, Vos DE, Gvasalia D, et al. Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol. 2010;11:69–86. doi:10.2174/13892011079072540120214609
   PubMed Web of Science ®Google Scholar
• Wittebole X, Roock DE, Opal SM. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence. 2014;5:226–235. doi:10.4161/viru.2599123973944
   PubMed Web of Science ®Google Scholar
• Pieterse L, Powers A, Pride D, Van Onselen L, Leone GE, Richardson PE. Investigating the lytic staphylococcus aureus bacteriophage reservoir amongst a south carolina university population: discovery, characterization, and identification of a potential bacteriophage treatment for methicillin-resistant staphylococcus aureus. J S C Acad Sci. 2018;16:8.
   Google Scholar
• Pincus NB, Reckhow JD, Saleem D, Jammeh ML, Datta SK, Myles IA. Strain specific phage treatment for Staphylococcus aureus infection is influenced by host immunity and site of infection. PLoS One. 2015;10:e0124280. doi:10.1371/journal.pone.012428025909449
   PubMed Web of Science ®Google Scholar
• Pires DP, Boas DV, Sillankorva S, Azeredo J. Phage therapy: a step forward in the treatment of Pseudomonas aeruginosa infections. J Virol. 2015;00385–15.
   Web of Science ®Google Scholar
• Lepelletier D, Berthelot P, Lucet J-C, et al. French recommendations for the prevention of ‘emerging extensively drug-resistant bacteria’(eXDR) cross-transmission. J Hosp Infect. 2015;90:186–195. doi:10.1016/j.jhin.2015.04.00225986165
   PubMed Web of Science ®Google Scholar
• Tan SY, Tatsumura Y. Alexander Fleming (1881–1881): discoverer of penicillin. Singapore medical journal. 2015;56:399.
   Web of Science ®Google Scholar
• Bodier-Montagutelli E, Morello E, L’Hostis G, et al. Inhaled phage therapy: a promising and challenging approach to treat bacterial respiratory infections. Expert Opin Drug Deliv. 2017;14:959–972. doi:10.1080/17425247.2017.125232927776446
   PubMed Web of Science ®Google Scholar
• Penesyan A, Gillings M, Paulsen IT. Antibiotic discovery: combatting bacterial resistance in cells and in biofilm communities. Molecules. 2015;20:5286–5298. doi:10.3390/molecules2004528625812150
   PubMed Web of Science ®Google Scholar
• Blaskovich MA, Pitt ME, Elliott AG, Cooper MA. Can octapeptin antibiotics combat extensively drug-resistant (XDR) bacteria? Expert Rev Anti Infect Ther. 2018;16:485–499. doi:10.1080/14787210.2018.148324029848132
   PubMed Web of Science ®Google Scholar
• Dorval Courchesne NM, Parisien A, Lan CQ. Production and application of bacteriophage and bacteriophage-encoded lysins. Recent Pat Biotechnol. 2009;3:37–45. doi:10.2174/18722080978717267819149721
   PubMedGoogle Scholar
• Hagens S, Loessner MJ. Application of bacteriophages for detection and control of foodborne pathogens. Appl Microbiol Biotechnol. 2007;76:513–519. doi:10.1007/s00253-007-1031-817554535
   PubMed Web of Science ®Google Scholar
• Nagel TE, Chan BK, De Vos D, et al. The developing world urgently needs phages to combat pathogenic bacteria. Front Microbiol. 2016;7:882. doi:10.3389/fmicb.2016.0088227375602
   PubMed Web of Science ®Google Scholar
• Lood R, Winer BY, Pelzek AJ, et al. Novel phage lysins capable of killing the multidrug resistant Gram-negative bacterium Acinetobacter baumannii in a mouse sepsis model. Antimicrob Agents Chemother. 2015;04641–14.
   Google Scholar
• Nakonieczna A, Cooper CJ, Gryko R. Bacteriophages and bacteriophage‐derived endolysins as potential therapeutics to combat Gram‐positive spore forming bacteria. J Appl Microbiol. 2015;119:620–631. doi:10.1111/jam.1288126109320
   PubMed Web of Science ®Google Scholar
• Pereira C, Moreirinha C, Teles L, et al. Application of phage therapy during bivalve depuration improves Escherichia coli decontamination. Food Microbiol. 2017;61:102–112. doi:10.1016/j.fm.2016.09.00327697159
   PubMed Web of Science ®Google Scholar
• Pabary R, Singh C, Morales S, et al. Anti-pseudomonal bacteriophage reduces infective burden and inflammatory response in murine lung. Antimicrob Agents Chemother. 2015;01426–15.
   Web of Science ®Google Scholar
• Górski A, Międzybrodzki R, Weber-Dąbrowska B, et al. Phage therapy: combating infections with potential for evolving from merely a treatment for complications to targeting diseases. Front Microbiol. 2016;7:1515. doi:10.3389/fmicb.2016.0151527725811
   PubMed Web of Science ®Google Scholar
• Nobrega FL, Costa AR, Kluskens LD, Azeredo J. Revisiting phage therapy: new applications for old resources. Trends Microbiol. 2015;23:185–191. doi:10.1016/j.tim.2015.01.00625708933
   PubMed Web of Science ®Google Scholar
• Shen G-H, Wang J-L, Wen F-S, et al. Isolation and characterization of φkm18p, a novel lytic phage with therapeutic potential against extensively drug resistant Acinetobacter baumannii. PLoS One. 2012;7:e46537. doi:10.1371/journal.pone.004653723071586
   PubMed Web of Science ®Google Scholar
• Bertozzi Silva J, Storms Z, Sauvageau D. Host receptors for bacteriophage adsorption. FEMS Microbiol Lett. 2016;363.
   Web of Science ®Google Scholar
• Woźnica WM, Bigos J, Łobocka MB. Lysis of bacterial cells in the process of bacteriophage release–canonical and newly discovered mechanisms. Postepy Hig Med Dosw (Online). 2015;69:114–126.25614679
   PubMedGoogle Scholar
• Drulis-Kawa Z, Majkowska-Skrobek G, Maciejewska B. Bacteriophages and phage-derived proteins–application approaches. Curr Med Chem. 2015;22:1757–1773. doi:10.2174/092986732266615020915285125666799
   PubMed Web of Science ®Google Scholar
• Dewey JS, Savva CG, White RL, Vitha S, Holzenburg A, Young R. Micron-scale holes terminate the phage infection cycle. Proc Natl Acad Sci. 2010;107:2219–2223. doi:10.1073/pnas.091403010720080651
   PubMed Web of Science ®Google Scholar
• Shi Y, Yan Y, Ji W, et al. Characterization and determination of holin protein of Streptococcus suis bacteriophage SMP in heterologous host. Virol J. 2012;9:70. doi:10.1186/1743-422X-9-7022436471
   PubMed Web of Science ®Google Scholar
• Pang T, Savva CG, Fleming KG, Struck DK, Young R. Structure of the lethal phage pinhole. Proc Natl Acad Sci. 2009;106:18966–18971. doi:10.1073/pnas.090794110619861547
   PubMed Web of Science ®Google Scholar
• Donovan DM, Foster-Frey J. LambdaSa2 prophage endolysin requires Cpl-7-binding domains and amidase-5 domain for antimicrobial lysis of streptococci. FEMS Microbiol Lett. 2008;287:22–33. doi:10.1111/fml.2008.287.issue-118673393
   PubMed Web of Science ®Google Scholar
• Linden SB, Zhang H, Heselpoth RD, et al. Biochemical and biophysical characterization of PlyGRCS, a bacteriophage endolysin active against methicillin-resistant Staphylococcus aureus. Appl Microbiol Biotechnol. 2015;99:741–752. doi:10.1007/s00253-014-5930-125038926
   PubMed Web of Science ®Google Scholar
• Tran TA, Struck DK, Young R. Periplasmic domains define holin-antiholin interactions in T4 lysis inhibition. J Bacteriol. 2005;187:6631–6640. doi:10.1128/JB.187.19.6631-6640.200516166524
   PubMed Web of Science ®Google Scholar
• Catalao MJ, Gil F, Moniz-Pereira J, Sao-Jose C, Pimentel M. Diversity in bacterial lysis systems: bacteriophages show the way. FEMS Microbiol Rev. 2013;37:554–571. doi:10.1111/1574-6976.1200623043507
   PubMed Web of Science ®Google Scholar
• Frias MJ, Melo-Cristino J, Ramirez M. The autolysin LytA contributes to efficient bacteriophage progeny release in Streptococcus pneumoniae. J Bacteriol. 2009;191:5428–5440. doi:10.1128/JB.00477-0919581370
   PubMed Web of Science ®Google Scholar
• De Smet J, Hendrix H, Blasdel BG, Danis-Wlodarczyk K, Lavigne R. Pseudomonas predators: understanding and exploiting phage–host interactions. Nat Rev Microbiol. 2017;15:517. doi:10.1038/nrmicro.2017.6128649138
   PubMed Web of Science ®Google Scholar
• Rozema EA, Stephens TP, Bach SJ, et al. Oral and rectal administration of bacteriophages for control of Escherichia coli O157: H7 in feedlot cattle. J Food Prot. 2009;72:241–250. doi:10.4315/0362-028X-72.2.24119350968
   PubMed Web of Science ®Google Scholar
• Ryan EM, Gorman SP, Donnelly RF, Gilmore BF. Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. J Pharm Pharmacol. 2011;63:1253–1264. doi:10.1111/j.2042-7158.2011.01324.x21899540
   PubMed Web of Science ®Google Scholar
• Vieira A, Silva Y, Cunha A, Gomes N, Ackermann H-W, Almeida A. Phage therapy to control multidrug-resistant Pseudomonas aeruginosa skin infections: in vitro and ex vivo experiments. Eur J Clin Microbiol Infect Dis. 2012;31:3241–3249. doi:10.1007/s10096-012-1691-x22777594
   PubMed Web of Science ®Google Scholar
• Regeimbal JM, Jacobs AC, Corey BW, et al. Personalized therapeutic cocktail of wild environmental phages rescues mice from A. baumannii wound infections. Antimicrob Agents Chemother. 2016;02877–15.
   Web of Science ®Google Scholar
• Jado I, López R, García E, Fenoll A, Casal J, García P. Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. J Antimicrob Chemother. 2003;52:967–973. doi:10.1093/jac/dkg48514613958
   PubMed Web of Science ®Google Scholar
• Biswas B, Adhya S, Washart P, et al. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun. 2002;70:204–210. doi:10.1128/IAI.70.1.204-210.200211748184
   PubMed Web of Science ®Google Scholar
• Vinodkumar C, Kalsurmath S, Neelagund Y. Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice. Indian J Pathol Microbiol. 2008;51:360. doi:10.4103/0377-4929.4251118723958
   PubMed Web of Science ®Google Scholar
• Danelishvili L, Young LS, Bermudez LE. In vivo efficacy of phage therapy for Mycobacterium avium infection as delivered by a nonvirulent mycobacterium. Microb Drug Resist. 2006;12:1–6. doi:10.1089/mdr.2006.12.116584300
   PubMed Web of Science ®Google Scholar
• Deng L, Yang Z, Gong Y, et al. Therapeutic effect of phages on extensively drug-resistant Acinetobacter baumannii-induced sepsis in mice. Zhonghua Shao Shang Za Zhi. 2016;32:523–528. doi:10.3760/cma.j.issn.1009-2587.2016.09.00327647067
   PubMedGoogle Scholar
• Morello E, Saussereau E, Maura D, Huerre M, Touqui L, Debarbieux L. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS One. 2011;6:e16963.21347240
   PubMed Web of Science ®Google Scholar
• Schooley RT, Biswas B, Gill JJ, et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2017;61:e00954–17. doi:10.1128/AAC.00954-1728807909
   PubMed Web of Science ®Google Scholar
• Ooi ML, Drilling AJ, Morales S, et al. Safety and tolerability of bacteriophage therapy for chronic rhinosinusitis due to staphylococcus aureus. JAMA Otolaryngol Head Neck Surg. 2019;145:723. doi:10.1001/jamaoto.2019.1191
   PubMed Web of Science ®Google Scholar
• Fish R, Kutter E, Wheat G, Blasdel B, Kutateladze M, Kuhl S. Bacteriophage treatment of intransigent diabetic toe ulcers: a case series. J Wound Care. 2016;25:S27–S33. doi:10.12968/jowc.2016.25.Sup7.S2726949862
   PubMed Web of Science ®Google Scholar
• Chan BK, Turner PE, Kim S, Mojibian HR, Elefteriades JA, Narayan D. Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evol Med Public Health. 2018;2018:60–66. doi:10.1093/emph/eoy00529588855
   PubMed Web of Science ®Google Scholar
• Jennes S, Merabishvili M, Soentjens P, et al. Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury—a case report. Crit Care. 2017;21:129. doi:10.1186/s13054-017-1709-y28583189
   PubMed Web of Science ®Google Scholar
• Letkiewicz S, Międzybrodzki R, Fortuna W, Weber-Dąbrowska B, Górski A. Eradication of Enterococcus faecalis by phage therapy in chronic bacterial prostatitis—case report. Folia Microbiol (Praha). 2009;54:457. doi:10.1007/s12223-009-0064-z19937220
   PubMed Web of Science ®Google Scholar
• Rhoads D, Wolcott R, Kuskowski MA, Wolcott B, Ward L, Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: results of a Phase I safety trial. J Wound Care. 2009;18:237–243. doi:10.12968/jowc.2009.18.6.4280119661847
   PubMedGoogle Scholar
• Wright A, Hawkins C, Änggård E, Harper D. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic‐resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol. 2009;34:349–357. doi:10.1111/coa.2009.34.issue-419673983
   PubMed Web of Science ®Google Scholar
• Schwarz S, Johnson AP. Transferable resistance to colistin: a new but old threat. J Antimicrob Chemother. 2016;71:2066–2070. doi:10.1093/jac/dkw27427342545
   PubMed Web of Science ®Google Scholar
• Azimi T, Shariati A, Fallah F, et al. Mycobacterium tuberculosis genotyping using MIRU-VNTR typing. J Mazandaran Univ Med Sci. 2017;27:40–48.
   Google Scholar
• Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol. 2006;55:1619–1629. doi:10.1099/jmm.0.46747-017108263
   PubMed Web of Science ®Google Scholar
• Magiorakos AP, Srinivasan A, Carey R, et al. Multidrug‐resistant, extensively drug‐resistant and pandrug‐resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–281. doi:10.1111/j.1469-0691.2011.03570.x21793988
   PubMed Web of Science ®Google Scholar
• Siegel JD, Rhinehart E, Jackson M, Chiarello L. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control. 2007;35:S165–S193. doi:10.1016/j.ajic.2007.10.00618068814
   PubMed Web of Science ®Google Scholar
• Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis. 2008;46:1121–1122. doi:10.1086/58799618444833
   PubMed Web of Science ®Google Scholar
• Kuo L-C, Teng L-J, Yu C-J, Ho S-W, Hsueh P-R. Dissemination of a clone of unusual phenotype of pandrug-resistant Acinetobacter baumannii at a university hospital in Taiwan. J Clin Microbiol. 2004;42:1759–1763. doi:10.1128/jcm.42.4.1759-1763.200415071042
   PubMed Web of Science ®Google Scholar
• Kuo L-C, Yu C-J, Lee L-N, et al. Clinical features of pandrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Taiwan. J Formos Med Assoc. 2003;102:601–606.14625603
   PubMed Web of Science ®Google Scholar
• Bahramian A, Khoshnood S, Shariati A, Doustdar F, Chirani AS, Heidary M. Molecular characterization of the pilS2 gene and its association with the frequency of Pseudomonas aeruginosa plasmid pKlc102 and PaPI-1 pathogenicity island. Infect Drug Resist. 2019a;12:221. doi:10.2147/IDR.S18852730666137
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U. Global antimicrobial resistance in Gram-negative pathogens and clinical need. Curr Opin Microbiol. 2017;39:106–112. doi:10.1016/j.mib.2017.10.02829154024
   PubMed Web of Science ®Google Scholar
• Shariati A, Azimi T, Ardebili A, et al. Insertional inactivation of oprD in carbapenem-resistant Pseudomonas aeruginosa strains isolated from burn patients in Tehran, Iran. New Microbes New Infect. 2018;21:75–80. doi:10.1016/j.nmni.2017.10.01329234497
   PubMedGoogle Scholar
• Talbot GH, Bradley J, Edwards JE JR, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the infectious diseases society of America. Clin Infect Dis. 2006;42:657–668. doi:10.1086/49981916447111
   PubMed Web of Science ®Google Scholar
• Dorman SE, Chaisson RE. From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis. Nat Med. 2007;13:295. doi:10.1038/nm0307-29517342143
   PubMed Web of Science ®Google Scholar
• Sebaihia M, Wren BW, Mullany P, et al. The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet. 2006;38:779. doi:10.1038/ng183016804543
   PubMed Web of Science ®Google Scholar
• Ardehali SH, Azimi T, Fallah F, Owrang M, Aghamohammadi N, Azimi L. Role of efflux pumps in reduced susceptibility to tigecycline in Acinetobacter baumannii. New Microbes New Infect. 2019;30.
   Google Scholar
• Mcgowan JE JR. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am J Infect Control. 2006;34:S29–S37. doi:10.1016/j.ajic.2006.05.22616813979
   PubMed Web of Science ®Google Scholar
• Pitout JD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159–166. doi:10.1016/S1473-3099(08)70041-018291338
   PubMed Web of Science ®Google Scholar
• Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999–2005. Emerg Infect Dis. 2007;13:1840.18258033
   PubMed Web of Science ®Google Scholar
• Arumugam SN, Rudraradhya AC, Sadagopan S, Sukumaran S, Sambasivam G, Ramesh N. Analysis of susceptibility patterns of pseudomonas aeruginosa and isolation, characterization of lytic bacteriophages targeting multi drug resistant pseudomonas aeruginosa. Biomed Pharmacol J. 2018;11:1105–1117.
   Google Scholar
• Rashel M, Uchiyama J, Ujihara T, et al. Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage ϕMR11. J Infect Dis. 2007;196:1237–1247. doi:10.1086/52130517955443
   PubMed Web of Science ®Google Scholar
• Latz S, Kruttgen A, Häfner H, Buhl EM, Ritter K, Horz H-P. Differential effect of newly isolated phages belonging to PB1-like, phiKZ-like and LUZ24-like viruses against multi-drug resistant pseudomonas aeruginosa under varying growth conditions. Viruses. 2017;9:315. doi:10.3390/v9110315
   Web of Science ®Google Scholar
• Golkar Z, Bagasra O, Jamil N. Experimental phage therapy on multiple drug resistant Pseudomonas aeruginosa infection in mice. J Antivir Antiretrovir. 2013: S10–005. doi, 10.
   Google Scholar
• Wang J, Hu B, Xu M, et al. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int J Mol Med. 2006;17:309–317.16391831
   PubMed Web of Science ®Google Scholar
• Jun JW, Shin TH, Kim JH, et al. Bacteriophage therapy of a Vibrio parahaemolyticus infection caused by a multiple-antibiotic–resistant O3: K6 pandemic clinical strain. J Infect Dis. 2014;210:72–78. doi:10.1093/infdis/jiu05924558119
   PubMed Web of Science ®Google Scholar
• Pouillot F, Chomton M, Blois H, et al. Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b: H4-ST131 Escherichia coli strain producing CTX-M-15. Antimicrob Agents Chemother. 2012;56:3568–3575.22491690
   PubMed Web of Science ®Google Scholar
• Wills QF, Kerrigan C, Soothill JS. Experimental bacteriophage protection against Staphylococcus aureus abscesses in a rabbit model. Antimicrob Agents Chemother. 2005;49:1220–1221. doi:10.1128/AAC.49.3.1220-1221.200515728933
   PubMed Web of Science ®Google Scholar
• Kwiatek M, Mizak L, Parasion S, Gryko R, Olender A, Niemcewicz M. Characterization of five newly isolated bacteriophages active against Pseudomonas aeruginosa clinical strains. Folia Microbiol (Praha). 2015;60:7–14. doi:10.1007/s12223-014-0333-324993480
   PubMed Web of Science ®Google Scholar
• Peng F, Mi Z, Huang Y, et al. Characterization, sequencing and comparative genomic analysis of vB_AbaM-IME-AB2, a novel lytic bacteriophage that infects multidrug-resistant Acinetobacter baumannii clinical isolates. BMC Microbiol. 2014;14:181. doi:10.1186/1471-2180-14-18124996449
   PubMed Web of Science ®Google Scholar
• Larche J, Pouillot F, Essoh C, et al. Rapid identification of international multidrug-resistant Pseudomonas aeruginosa clones by multiple-locus variable number of tandem repeats analysis and investigation of their susceptibility to lytic bacteriophages. Antimicrob Agents Chemother. 2012;56:6175–6180.22985882
   PubMed Web of Science ®Google Scholar
• Shokri D, Soleimani-Delfan A, Fatemi SM. Assessment of phage cocktails with extended host range activity against antibiotic resistant strains of Pseudomonas aeruginosa. Comp Clin Path. 2017;26:417–422. doi:10.1007/s00580-016-2394-y
   Google Scholar
• Bai C, Liu Y, Mi Z, Tong Y. Potential of the phage depolymerase from a myoviridae bacteriophage vB_AbaM_IME200 against pandrug-resistant acinetobacter Baumannii. In: C60 Translational and Basic Investigations in Pulmonary Infection American Thoracic Society; 2018:A5488–A5488.
   Google Scholar
• Comeau AM, Tetart F, Trojet SN, Prere M-F, Krisch H. Phage-antibiotic synergy (PAS): β-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS One. 2007;2:e799. doi:10.1371/journal.pone.000079917726529
   PubMed Web of Science ®Google Scholar
• Djurkovic S, Loeffler JM, Fischetti VA. Synergistic killing of Streptococcus pneumoniae with the bacteriophage lytic enzyme Cpl-1 and penicillin or gentamicin depends on the level of penicillin resistance. Antimicrob Agents Chemother. 2005;49:1225–1228. doi:10.1128/AAC.49.3.1225-1228.200515728935
   PubMed Web of Science ®Google Scholar
• Kelly D, Mcauliffe O, Ross R, Coffey A. Prevention of Staphylococcus aureus biofilm formation and reduction in established biofilm density using a combination of phage K and modified derivatives. Lett Appl Microbiol. 2012;54:286–291. doi:10.1111/lam.2012.54.issue-422251270
   PubMed Web of Science ®Google Scholar
• Khalifa L, Brosh Y, Gelman D, et al. Targeting Enterococcus faecalis biofilm using phage therapy. Appl Environ Microbiol. 2015;00096–15.
   Web of Science ®Google Scholar
• Kirby AE. Synergistic action of gentamicin and bacteriophage in a continuous culture population of Staphylococcus aureus. PLoS One. 2012;7:e51017. doi:10.1371/journal.pone.005101723226451
   PubMed Web of Science ®Google Scholar
• Loeffler J, Fischetti V. Synergistic lethal effect of a combination of phage lytic enzymes with different activities on penicillin-sensitive and-resistant Streptococcus pneumoniae strains. Antimicrob Agents Chemother. 2003;47:375–377. doi:10.1128/AAC.47.1.375-377.200312499217
   PubMed Web of Science ®Google Scholar
• Oechslin F, Piccardi P, Mancini S, et al. Synergistic interaction between phage therapy and antibiotics clears Pseudomonas aeruginosa infection in endocarditis and reduces virulence. J Infect Dis. 2016;215:703–712.
   Web of Science ®Google Scholar
• Ryan EM, Alkawareek MY, Donnelly RF, Gilmore BF. Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro. FEMS Immunol Med Microbiol. 2012;65:395–398. doi:10.1111/j.1574-695X.2012.00977.x22524448
   PubMedGoogle Scholar
• Verma V, Harjai K, Chhibber S. Restricting ciprofloxacin-induced resistant variant formation in biofilm of Klebsiella pneumoniae B5055 by complementary bacteriophage treatment. J Antimicrob Chemother. 2009;64:1212–1218. doi:10.1093/jac/dkp36019808232
   PubMed Web of Science ®Google Scholar
• Yele AB, Thawal ND, Sahu PK, Chopade BA. Novel lytic bacteriophage AB7-IBB1 of Acinetobacter baumannii: isolation, characterization and its effect on biofilm. Arch Virol. 2012;157:1441–1450. doi:10.1007/s00705-012-1320-022552486
   PubMed Web of Science ®Google Scholar
• Rohde C, Resch G, Pirnay J-P, et al. Expert opinion on three phage therapy related topics: bacterial phage resistance, phage training and prophages in bacterial production strains. Viruses. 2018;10:178. doi:10.3390/v10040178
   PubMed Web of Science ®Google Scholar
• Susskind MM, Wright A, Botstein D. Superinfection exclusion by P22 prophage in lysogens of Salmonella typhimurium: II. Genetic evidence for two exclusion systems. Virology. 1971;45:638–652. doi:10.1016/0042-6822(71)90178-44942206
   PubMed Web of Science ®Google Scholar
• Drulis-Kawa Z, Majkowska-Skrobek G, Maciejewska B, Delattre A-S, Lavigne R. Learning from bacteriophages-advantages and limitations of phage and phage-encoded protein applications. Curr Protein Pept Sci. 2012;13:699–722. doi:10.2174/13892031280487119323305359
   PubMed Web of Science ®Google Scholar
• Labrie SJ, Samson JE, Moineau S. Bacteriophage resistance mechanisms. Nat Rev Microbiol. 2010;8:317. doi:10.1038/nrmicro231520348932
   PubMed Web of Science ®Google Scholar
• Sekulovic O, Ospina Bedoya M, Fivian‐Hughes AS, Fairweather NF, Fortier LC. The C lostridium difficile cell wall protein CwpV confers phase‐variable phage resistance. Mol Microbiol. 2015;98:329–342. doi:10.1111/mmi.1312126179020
   PubMed Web of Science ®Google Scholar
• Chapman-Mcquiston E, Wu X. Stochastic receptor expression allows sensitive bacteria to evade phage attack. Part I: experiments. Biophys J. 2008;94:4525–4536. doi:10.1529/biophysj.107.12021218310238
   PubMed Web of Science ®Google Scholar
• Mahmud RS, Mindubaeva L, Ulyanova V, Khazieva L, Vargas H, Ilinskaya O. Antibacteriophage action of Bacillus altitudinis extracellular ribonuclease. FEBS J. 2016;283:58–123.
   Web of Science ®Google Scholar
• Chaudhary K. BacteRiophage EXclusion (BREX): a novel anti‐phage mechanism in the arsenal of bacterial defense system. J Cell Physiol. 2018;233:771–773. doi:10.1002/jcp.2597328444888
   PubMed Web of Science ®Google Scholar
• Hoque MM, Naser IB, Bari SN, Zhu J, Mekalanos JJ, Faruque SM. Quorum regulated resistance of Vibrio cholerae against environmental bacteriophages. Sci Rep. 2016;6:37956. doi:10.1038/srep3795627892495
   PubMed Web of Science ®Google Scholar
• Tan D, Svenningsen SL, Middelboe M. Quorum sensing determines the choice of antiphage defense strategy in Vibrio anguillarum. MBio. 2015;6:e00627–15. doi:10.1128/mBio.00627-1526081633
   PubMed Web of Science ®Google Scholar
• Ofir G, Melamed S, Sberro H, et al. DISARM is a widespread bacterial defence system with broad anti-phage activities. Nat Microbiol. 2018;3:90. doi:10.1038/s41564-017-0051-029085076
   PubMed Web of Science ®Google Scholar
• Chopin M-C, Chopin A, Bidnenko E. Phage abortive infection in lactococci: variations on a theme. Curr Opin Microbiol. 2005;8:473–479. doi:10.1016/j.mib.2005.06.00615979388
   PubMed Web of Science ®Google Scholar
• Fineran PC, Blower TR, Foulds IJ, Humphreys DP, Lilley KS, Salmond GP. The phage abortive infection system, ToxIN, functions as a protein–RNA toxin–antitoxin pair. Proc Natl Acad Sci. 2009;106:894–899. doi:10.1073/pnas.080883210619124776
   PubMed Web of Science ®Google Scholar
• Samson JE, Belanger M, Moineau S. Effect of the abortive infection mechanism and type III toxin/antitoxin system AbiQ on the lytic cycle of Lactococcus lactis phages. J Bacteriol. 2013;00296–13.
   Web of Science ®Google Scholar
• Martínez-Rubio R, QUILES-PUCHALT N, MARTí M, et al. Phage-inducible islands in the Gram-positive cocci. ISME J. 2017;11:1029. doi:10.1038/ismej.2016.16327959343
   PubMed Web of Science ®Google Scholar
• Penades JR, Christie GE. The phage-inducible chromosomal islands: a family of highly evolved molecular parasites. Annl Rev Virol. 2015;2:181–201. doi:10.1146/annurev-virology-031413-08544626958912
   PubMed Web of Science ®Google Scholar
• Seed KD. Battling phages: how bacteria defend against viral attack. PLoS Pathog. 2015;11:e1004847. doi:10.1371/journal.ppat.100484726066799
   PubMed Web of Science ®Google Scholar
• Bondy-Denomy J, Garcia B, Strum S, et al. Multiple mechanisms for CRISPR–cas inhibition by anti-CRISPR proteins. Nature. 2015;526:136. doi:10.1038/nature1525426416740
   PubMed Web of Science ®Google Scholar
• Obeng N, Pratama AA, Van Elsas JD. The significance of mutualistic phages for bacterial ecology and evolution. Trends Microbiol. 2016;24:440–449. doi:10.1016/j.tim.2015.12.00926826796
   PubMed Web of Science ®Google Scholar
• Samson JE, Magadán AH, Sabri M, Moineau S. Revenge of the phages: defeating bacterial defences. Nat Rev Microbiol. 2013;11:675. doi:10.1038/nrmicro309623979432
   PubMed Web of Science ®Google Scholar
• Tzipilevich E, Habusha M, Ben-Yehuda S. Acquisition of phage sensitivity by bacteria through exchange of phage receptors. Cell. 2017;168:186–199. e12. doi:10.1016/j.cell.2016.12.00328041851
   PubMed Web of Science ®Google Scholar
• Bondy-Denomy J, Pawluk A, Maxwell KL, Davidson AR. Bacteriophage genes that inactivate the CRISPR/Cas bacterial immune system. Nature. 2013;493:429. doi:10.1038/nature1172323242138
   PubMed Web of Science ®Google Scholar
• Hynes AP, Rousseau GM, Lemay M-L, et al. An anti-CRISPR from a virulent streptococcal phage inhibits Streptococcus pyogenes Cas9. Nat Microbiol. 2017;2:1374. doi:10.1038/s41564-017-0004-728785032
   PubMed Web of Science ®Google Scholar
• Landsberger M, Gandon S, Meaden S, et al. Anti-CRISPR phages cooperate to overcome CRISPR-Cas immunity. Cell. 2018;174:908–916. e12. doi:10.1016/j.cell.2018.05.05830033365
   PubMed Web of Science ®Google Scholar
• Seed KD, Lazinski DW, Calderwood SB, Camilli A. A bacteriophage encodes its own CRISPR/Cas adaptive response to evade host innate immunity. Nature. 2013;494:489. doi:10.1038/nature1192723446421
   PubMed Web of Science ®Google Scholar
• Örmälä A-M, Jalasvuori M. Phage therapy: should bacterial resistance to phages be a concern, even in the long run? Bacteriophage. 2013;3:e24219. doi:10.4161/bact.2421923819105
   PubMedGoogle Scholar
• Pirnay J-P, Blasdel BG, Bretaudeau L, et al. Quality and safety requirements for sustainable phage therapy products. Pharm Res. 2015;32:2173–2179. doi:10.1007/s11095-014-1617-725585954
   PubMed Web of Science ®Google Scholar
• Oliveira J, Castilho F, Cunha A, Pereira M. Bacteriophage therapy as a bacterial control strategy in aquaculture. Aquacult Int. 2012;20:879–910.
   Web of Science ®Google Scholar
• Weld RJ, Butts C, Heinemann JA. Models of phage growth and their applicability to phage therapy. J Theor Biol. 2004;227:1–11. doi:10.1016/S0022-5193(03)00262-514969703
   PubMed Web of Science ®Google Scholar
• Gorski A, Miedzybrodzki R, Borysowski J, et al. Bacteriophage therapy for the treatment of infections. Curr Opin Investig Drugs. 2009;10:766–774.
   PubMedGoogle Scholar
• Międzybrodzki R, Borysowski J, Weber-Dąbrowska B, et al. Clinical aspects of phage therapy. Adv Virus Res. 2012 Elsevier.
   Web of Science ®Google Scholar
• Stafford N. Switzerland is to fund complementary therapies for six years while effectiveness is evaluated. BMJ. 2011;35:569–583.
   Google Scholar